Rubidomycin in Acute Leukaemia Foods

3 June 1967 Leading Articles BRnITH 587 sympathetic efferent function should be given. These com- pathetic blocking agents will give better results than a single prise the ganglion-blocking agents, of which only mecamyl- one.'4 Good results depend to a great extent on the care with amine and pempidine are now used in any quantity, methyl- which the regimen is managed: this is usually more impor- Br Med J: first published as 10.1136/bmj.2.5552.587 on 3 June 1967. Downloaded from dopa, and the drugs which block sympathetic fibres at the tant than the initial choice of drug. neuro-effector junction-bretylium, guanethidine, bethanidine, guanoxan, guanoclor, and debrisoquine. Pargyline has an effect similar to these drugs on arterial pressure,' but should not usually be prescribed for the maintenance treatment of hypertensive patients because it is a monoamine- oxidase inhibitor, and patients receiving drugs of this type may suffer dangerous reactions after some other drugs or Rubidomycin in Acute Leukaemia foods. The ganglion-blocking drugs affect parasympathetic as well as sympathetic functions and thus may cause addi- Rubidomycin is the first antibiotic to show therapeutic effect tional side-effects. Few people would now consider them the in management of acute leukaemia in man. It is produced first choice for the treatment of severe hypertension, though from a strain of Streptomyces coeruleorubidus, and it is active they may be very useful if other drugs fail. Bretylium has in all forms of acute leukaemia. J. Bernard and his now fallen into disfavour because many patients become colleagues,' in an extensive clinical trial, have found it useful tolerant of its hypotensive effects. in the treatment of acute lymphoblastic leukaemia and have In the B.M.7. this week Dr. V. Vejlsgaard and his col- also been able to obtain remission in more than half their leagues report a double-blind comparison of four drugs- patients with acute myeloblastic leukaemia. This is the first namely, guanethidine, methyldopa, guanoxan, and guanoclor. time that the use of one drug alone has resulted in such a Most studies of different ganglion-blocking agents have con- satisfactory remission rate in acute myeloblastic leukaemia, centrated on the severity of postural hypotension, and the and the duration of the remissions appears to be at least incidence of side-effects over a relatively short period of time. several months. The present workers found methyldopa the most satisfactory Several schedules for the administration of rubidomycin in these respects. In a similar comparison between methyl- are being tried, and it is not yet possible to define the most dopa, guanethidine, and pargyline7 the same conclusion was satisfactory method. It is now agreed, however, that remission reached, though there was much variation between patients. should be induced by the shortest possible course and that About two-thirds of the patients were better controlled by maintenance therapy is contraindicated because of the drug's methyldopa than either of the other drugs, but one-third of toxic effects on the heart. Remissions may be induced by the them did better on one of the other agents. This merely intravenous administration of the drug dissolved in saline and underlines the fact that no ideal drug exists. Vejlsgaard and injected into a fast-flowing infusion. The injection is given his associates have shown convincingly that guanoclor is a daily in a dose of 1 to 2 mg. per kilogram body weight per difficult drug to use for the maintenance treatment of hyper- day, the length of the course depending on how well it is tolerated. The maximum dose that should be given is about tension, and it seems unwise to employ it unless others fail http://www.bmj.com/ to give satisfactory results. Though guanoxan performed 20 mg. per kilogram body weight, the average dose before fairly well in their hands, impaired liver function has now been side-effects are encountered being 6 to 10 mg. per kilogram. observed in many patients receiving it,8-0 and it may be wise So far the major complications encountered have been to give it too only if other agents fail. cardiotoxicity and bone-marrow aplasia. Toxic effects on This leaves methyldopa, guanethidine, bethanidine, and the heart first show themselves by tachycardia, which leads debrisoquine. The last two have not been formally com- rapidly to pulmonary oedema and death. Death from pared with other drugs, but of the first two methyldopa myocardial degeneration induced by rubidomycin has appears to have a marginal advantage." However, it also occurred in about 10% of patients treated so far.' 2 The on 25 September 2021 by guest. Protected copyright. has some drawbacks. Between 10% and 30% of patients onset of this complication does not appear to be preceded by receiving long-term treatment develop a positive reaction to electrocardiographic abnormalities, and heart failure when it the Coombs test, and a small proportion of these have haemo- occurs is of sudden onset and intractable. Its occurrence is lytic anaemia.'2 There is also a risk of drug fever and liver related to the total dose given and has been seen in patients damage." In some patients it is impossible to control the given maintenance therapy or when a large dose was required blood pressure with methyldopa, even in combination with a to obtain a remission. diuretic. Many different remedies will need to be tried in Aplasia of the bone marrow is severe and occurs in a large difficult cases, and sometimes a combination of two sym- proportion of patients treated, G. Mathe having noted an Leishman, A. W. D., Lancet, 1963, 1, 1284. incidence as high as 90%.' It is more likely to occur in those 2 Hamilton, M., Thompson, E. N., and Wisniewski, T. K. M., ibid., patients who have had a number of chemotherapeutic agents 1964, 1, 235. Levine, R. J., and Strauch, B. S., New Engl. 7. Med., 1966, 275, 946. before starting rubidomycin, or in whom bone-marrow smears Cooper, E. H., and Cranston, W. I., Lancet, 1957, 1, 396. are not very cellular at the start of therapy. Aplasia Chesrow, E. J., Bernstein, M., Wiess, D., and Marquardt, G. H., Amer. 7. med. Sci., 1966, 251, 166. commonly arises during the second week of treatment and Prichard, B. N. C., and Gillam, P. M. S., Brit. med. 7., 1964, 2, 725. requires with Oates, J. A., Seiann, A. W., Clark, M. A., Rousseau, P., and Lee, supportive therapy antibiotics and transfusions R. E., New Engl. 7. Med., 1965, 273, 729. of platelets and white cells. The alternative is to nurse the ' Montuschi, E., and Lovel, T. W. I., Lancet, 1964, 2, 1339. ' Sheps, S. G., Schirger, A., Osmundson, P. J., Kavanaugh, G. J. patient in a germ-free environment and to give blood and Fairbairn, J. F., and Burbank, M. K., Mayo ClGn. Proc., 1966, 41, 577. platelet transfusions when necessary. 10 Cotton, S. G., and Montuschi, E., Brit. med. Y., 1966, 1, 51. Johnson, P., Kitchin, A. H., Lowther, C. P., and Turner, R. W. D., Hence rubidomycin is a very powerful therapeutic agent ibid.? 1966, 1, 133. which warrants further Carstairs, K. C., Breckenridge, A., Dollery, C. T., and Worlledge, tial. Its use at the present time S. M., Lancet, 1966, 2, 133. 3 Sjoerdsma, A., in Antihypertensive Therapy, ed. F. Gross, p. 321. XBernard, J., Jacquillt, C, Boiron M., Najean, Y.I Seligmann, i., 1966. Berlin. Tanzer, J., Wel, M., and L1ortholary, P., Presse med., 1967a,7, 951. ". Breckenridge, A., and Dollery, C. T., Lancet, 1966, 1, 1074. 2 Mathi, G., unpublished observations. 588 3 June 1967 Leading Articles would seem to be in those patients with acute lymphoblastic without any diminution of the blocking effect on the euphoro- leukaemia who are no longer responsive to conventional genic and dependence-producing properties of morphine treatment and yet have an adequate bone-marrow reserve. suggested the use of cyclazocine as an extension of the " drug- Br Med J: first published as 10.1136/bmj.2.5552.587 on 3 June 1967. Downloaded from One further conventional drug should be available to maintain free environment " approach to treatment. Cyclazocine can any remission obtained by rubidomycin. It would seem that provide a method of enforcing and maintaining a state of rubidomycin offers the best chance of inducing a remission in abstinence. A heroin addict taking a dose of 4 mg. cycla- acute myeloblastic leukaemia provided full supportive therapy zocine daily is immune to the usual euphoric and systemic is available. effects of a challenge dose of 15 mg. heroin."' The potential of cyclazocine for abuse is considerably lower than that of most narcotic drugs. Stabilized patients can be permitted considerably more latitude in their contact with treatment New Treatments for Heroin centres. Preliminary reports of clinical trials in New York confirm the possible future usefulness of this drug.' Addiction The use of cyclazocine is still in the experimental stage. Recent reportsl'3 from New York describe the treatment of Maintenance on methadone has now been used in New York heroin addicts by maintenance with methadone-a long- for three years. The follow-up of the group treated has been acting opiate which can be taken orally. V. P. Dole and his the most thorough reported so far, and the results the most colleagues found that with the blockade produced by a single promising. At a time when the Ministry of Health is starting daily maintenance dose of 100 mg. methadone patients became to set up special outpatient clinics which will provide refractory to the euphoric action of 80 mg. or more of heroin, maintenance supplies of heroin for addicts"I there is an urgent an amount equivalent to the drug contained in several illegal need for controlled trials of all forms of treatment of heroin " bags " in New York.

Load more